NEW YORK , NY / ACCESSWIRE / January 24, 2018 / Inovio was one of the best performing stocks in the market yesterday after the company revealed published data that was encouraging regarding its goal of creating a universal flu vaccine. Shares of CytRX Corporation also skyrocketed despite any big news but last week the company did announce the dosing of the first patient in the licensee NantCell clinical trial.

RDI Initiates Coverage on:

Inovio Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=INO

CytRx Corporation
https://rdinvesting.com/news/?ticker=CYTR

Inovio Pharmaceuticals, Inc. shares closed up 22.63% on about 7.1 million shares traded. The stock saw big gains after the company reported promising data on Monday. The company is working on developing a universal flu vaccine and the data published had traders feeling optimistic. According to Inovio, the synthetic vaccine methodology led to favorable responses in generating protective antibodies against major variations of the influenza virus. This included the infamous Spanish flu of 1918. Dr. Laurent Humeau, the company's Sr. VP, Research and Development, said, "Funded by a grant from the NIH, this published work demonstrates that Inovio's ASPIRE? (Antigen SPecific Immune REsponses) technology platform could produce a universal flu vaccine that can span seasonal vaccine changes allowing for continued immune protection. We are proud to advance Inovio technology and contribute to advance cutting edge technology for the important global health treats. These studies also showcase the latest CELLECTRA® intradermal (skin) delivery system to facilitate optimal antigen production and generation of superior immune responses in animal models."

Access RDI's Inovio Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INO

CytRx Corporation shares closed up 24.04% on Tuesday and was one of the biggest gainers on the NASDAQ. Trading volume was explosive yesterday with volume nearly seven times higher than usual. The company didn't have any significant news yesterday but last week announced that NantCell, Inc., a aldoxorubicin licnesee, and a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with metastatic pancreatic cancer. CytRx's Chairman and CEO Steven A. Kriegsman remarked, "NantCell's decision to include aldoxorubicin in this new trial speaks to their commitment to expanding its potential use in combination with immuno-oncology agents and cell-based therapies." The trial, which is expected to enroll 173 patients, has a primary endpoint for safety in Phase 1b and a primary endpoint of objective response rate by RECIST in the Phase 2 portion. Aldoxorubicin is a tumor-targeted doxorubicin conjugate in development by CytRx.

Access RDI's CytRx Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CYTR

Our Actionable Research on Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CytRx Corporation (NASDAQ: CYTR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com